NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
about
Ketamine: 50 Years of Modulating the MindKetamine's antidepressant action: beyond NMDA receptor inhibitionA Clickable Analogue of Ketamine Retains NMDA Receptor Activity, Psychoactivity, and Accumulates in Neurons.A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.Differential Behavioral and Neurobiological Effects of Chronic Corticosterone Treatment in Adolescent and Adult RatsTransient anhedonia phenotype and altered circadian timing of behaviour during night-time dim light exposure in Per3-/- mice, but not wildtype mice.Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state.Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine.S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression.How do antidepressants work? New perspectives for refining future treatment approaches.Experimental medication treatment approaches for depression.Animal models to improve our understanding and treatment of suicidal behaviorDecreased Nucleus Accumbens Expression of Psychiatric Disorder Risk Gene Cacna1c Promotes Susceptibility to Social StressSignaling pathways underlying the antidepressant-like effect of inosine in miceAntidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonismThe Link between Depression and Chronic Pain: Neural Mechanisms in the Brain.Investigational drugs in recent clinical trials for treatment-resistant depression.Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.The interactive effects of ketamine and magnesium upon depressive-like pathology.Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies.Depression: Ketamine steps out of the darknessConsidering Sex as a Biological Variable Will Be Valuable for Neuroscience ResearchThe Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models.Ketamine: NMDA Receptors and Beyond.Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model.ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression.Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13).Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model.RNA-sequencing profiles hippocampal gene expression in a validated model of cancer-induced depression.Backing into the future: pharmacological approaches to the management of resistant depressionNeuropathology of suicide: recent findings and future directions.Ketamine as an adjuvant to opioids for cancer pain.Sex-dependent effects of stress on immobility behavior and VTA dopamine neuron activity: modulation by ketamine.Targeting glutamate signalling in depression: progress and prospects.Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular ActionsAnhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials.Kinase-mediated signaling cascades in mood disorders and antidepressant treatment.
P2860
Q28077524-002447EB-B55C-4CD8-AC66-8ED7EFC45FDAQ28278684-37588CEF-BECB-46D8-B333-74F9136EED29Q28817259-99C4826A-8E6F-410F-AAD0-F47B23B52266Q30361531-08566211-55D0-42CA-B21D-404ED08C6028Q30363153-D652BCCB-639C-404C-AFE4-C8DCD65ABCB6Q30834441-0ABA959F-41BD-4DE0-9E98-FD17F05FD249Q30848010-871D2F66-D232-4039-9011-9C1B175CFB4AQ30855337-3C9BA37D-D9FE-4686-8DAD-5353F4C6D935Q33614231-4D03CDAA-CAC7-49AE-9144-FDF734020B39Q33619029-CAE31D27-E7A1-45E2-BF13-24F3BA7FB2BCQ33635577-6A322A58-C765-404A-925F-29C573B18C69Q33635653-930B6395-12FA-4992-94D6-9DA39FF4C632Q33636522-19A25C37-2514-4894-8D46-74FFF53A8A68Q33689441-32469A19-2562-489C-9F6D-58937520F4BCQ33842686-11C71672-A3D4-4B3C-9466-1A9A828B0EB2Q33863747-C94536E2-730F-4CCF-A719-014A800BA11DQ34549390-D9779596-371E-436C-BE93-B99AF990687BQ34551188-4FB8F2E5-5754-435F-B09F-CF92CA302091Q37249086-5CCC588C-4E71-40CC-9A5B-3D8EE212902BQ37279054-57AC9FFB-29CE-4A44-9E1F-3773B9D7F6FEQ37398383-4B1F20C0-4CE6-4332-B4E3-777BE8BD91E9Q37403546-198080C3-7267-4813-83F0-28C94FF3F618Q37445074-55221457-1214-4D6A-9C1F-8EB9B6D8AAFAQ37490383-F26157CA-1339-47E0-98FE-3791EF5C2129Q37490388-49A3B565-3B43-4C69-87B3-7391E0914590Q37547285-D46C3898-8493-4C7C-A771-152E0C731AF8Q37583961-5E983E84-F56E-4B58-9724-8AD637CEFFC1Q37709284-19FE5F38-EBDB-4E5D-8908-8EAE9EF51C96Q37722650-658214DD-FB04-44A6-8A0D-19224B680BC3Q37741989-2EFF418D-9125-4FE5-87BE-9DEDF63698C7Q37745437-4C71EF5F-45AF-4820-9F32-E74777A1867BQ38443525-B92C0248-E9EE-4FED-85DF-2260841CA687Q38637621-5094E933-6859-4001-AE66-10BC24C87A95Q38659366-E1128378-BC21-4785-ABEC-55A8C2D83FC9Q38705422-620EEBCF-4B57-4D41-B0F1-1FBB3F454CFEQ38737919-0F3D9C32-8A31-42A2-9B27-82142700403DQ38743867-DB1F6DE3-68AA-4A9F-9344-D8E9C54E72BCQ38770806-B2D1A5D7-E2DB-486D-88AB-001E775845C9Q38800909-7EA54A3F-5E67-46D2-A108-8DA2BF08DBABQ38804430-F98AE80F-63D5-4E74-A700-85AC46EDB529
P2860
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
@ast
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
@en
type
label
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
@ast
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
@en
prefLabel
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
@ast
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
@en
P2093
P2860
P356
P1433
P1476
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
@en
P2093
Carlos A Zarate
Cheryl L Mayo
Craig J Thomas
Edson X Albuquerque
Heather J Pribut
Irving W Wainer
Jonathan Fischell
Katina S S Dossou
Manickavasagom Alkondon
Nagendra S Singh
P2860
P2888
P304
P356
10.1038/NATURE17998
P407
P577
2016-05-04T00:00:00Z
P6179
1000824623